These findings suggest that O-glycosylation enzymes are viable therapeutic targets for overcoming ferroptosis resistance and that GALNT14 expression levels may serve as biomarkers for predicting treatment responses in ovarian cancer patients [77,81]. This evidence concerns the gene GALNT14 and ovarian cancer.